Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Sparsentan (Primary) ; Irbesartan
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms DUET
- Sponsors Travere Therapeutics
- 22 Apr 2024 Status changed from active, no longer recruiting to completed.
- 19 Apr 2024 This study has been Completed in Belgium, According to European Clinical Trials Database record.
- 23 Mar 2023 According to Travere Therapeutics media release, data from open-label extension part of this study will be presented in late-breaking trial sessions at both the ISN World Congress of Nephrology in Bangkok, Thailand, March 30-April 2 (ISN-WCN), and NKF Spring Clinical Meetings in Austin, TX